Search research articles
Contact Us
Filters
Showing results (101-110 of 137) with videos related to
Page
of 14
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
April 8, 2026
Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies
W Hudson Robb, Gurkiran Kaur, Steven Huang, et al.
European Journal of Heart Failure
|
September 20, 2024
In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial
Maria A Pabon, Muthiah Vaduganathan, Brian L Claggett, et al.
Global Heart
|
June 4, 2020
WHF IASC Roadmap on Chagas Disease
Luis Eduardo Echeverría, Rachel Marcus, Gabriel Novick, et al.
JACC. Heart Failure
|
August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction
Sara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
Critical Care (London, England)
|
January 4, 2022
Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial
Mario G Santamarina, Ignacio Beddings, Felipe Martinez Lomakin, et al.
The Lancet. Diabetes & Endocrinology
|
November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Silvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
European Journal of Heart Failure
|
May 22, 2023
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials
Ankeet S Bhatt, Mikhail N Kosiborod, Muthiah Vaduganathan, et al.
JAMA Cardiology
|
March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
Kirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
European Heart Journal
|
May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
JACC. Heart Failure
|
July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
Scott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 137) with videos related to
Sort By:
Page
of 14
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
April 8, 2026
Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies
W Hudson Robb, Gurkiran Kaur, Steven Huang, et al.
European Journal of Heart Failure
|
September 20, 2024
In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial
Maria A Pabon, Muthiah Vaduganathan, Brian L Claggett, et al.
Global Heart
|
June 4, 2020
WHF IASC Roadmap on Chagas Disease
Luis Eduardo Echeverría, Rachel Marcus, Gabriel Novick, et al.
JACC. Heart Failure
|
August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction
Sara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
Critical Care (London, England)
|
January 4, 2022
Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial
Mario G Santamarina, Ignacio Beddings, Felipe Martinez Lomakin, et al.
The Lancet. Diabetes & Endocrinology
|
November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Silvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
European Journal of Heart Failure
|
May 22, 2023
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials
Ankeet S Bhatt, Mikhail N Kosiborod, Muthiah Vaduganathan, et al.
JAMA Cardiology
|
March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
Kirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
European Heart Journal
|
May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
JACC. Heart Failure
|
July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
Scott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
Page
of 14